Roche Holding AG

Roche Holding AG

Grenzacherstrasse 124

4058Basel

    • Rechtsform:

    • Aktiengesellschaft
    • Status:

    • aktiv

    • Kapitalisierung:

    • CHF 160'000'000.00
    • Gründungsjahr:

    • 1896

    • D-U-N-S® Nr.:

    • 48-000-8226

Nachfolgend sowie unter den weiteren Menüpunkten finden Sie alle wichtigen Informationen über die Roche Holding AG. Neben öffentlichen Daten finden Sie auch Informationen zu Zahlungserfahrungen, Geschichte, Firmenstruktur und Finanzen sowie zur Vernetzung der verantwortlichen Personen.

Schauen Sie genauer hin!

screen_bonitaetsauskunft

Bonität & Betreibungen

Mehr zur Zahlungsfähigkeit erfahren und Überraschungen vermeiden.

Kostenlose Firmen-Überwachung

Wir informieren Sie über wichtige Änderungen.

Handelsregister

    • Handelsregistereintrag:

    • 15.09.1995

    • Rechtlicher Sitz:

    • 4000 Basel

    • HR-Nummer:

    • CH-270.3.005.159-0

    • UID:

    • CHE-101.602.521

    • HR-Amt:

    • Kanton Basel-Stadt

    • Revisionsstelle:

    • KPMG AG

Management & Mitarbeiter

Finanzielles

    • Bonitätsauskunft:

    • Informieren Sie sich hier über die Kreditwürdigkeit, Bonität und Zahlungsfähigkeit der Firma Roche Holding AG.

      Zur Roche Holding AG konnten wir das Zahlungsverhalten zu insgesamt 131 Rechnungen auswerten.

      Bonität prüfen
    • Betreibungsauszug:

    • Es liegt uns noch kein Betreibungsauszug vor.

      Sie möchten wissen, ob zur Firma Roche Holding AG Betreibungen am Register verzeichnet sind? Gerne holen wir für Sie beim zuständigen Betreibungsamt einen aktuellen Auszug ein, den Sie hier bestellen können.

      Betreibungsauskunft bestellen
    • Risiko-Analyse:

    • Sie mögen alle Infos auf einen Blick? In der Risiko-Analyse zur Roche Holding AG haben Sie Bonität, Score, reelle Zahlungserfahrungen und einen Betreibungsauszug in einem Bericht.

      Risiko-Analyse einsehen
    • Bonitäts-Zertifikat:

    • Firmen, welche über mehrere Jahre eine hohe Bonität ausweisen, können diese mit einer Urkunde bestätigen lassen.

      Bonitäts-Zertifikat

Firmennamen & Kontakt

    • Aktueller Firmenname:

    • Roche Holding AG

    • Aktuelle Adresse:

    • Grenzacherstrasse 124

      4058 Basel

    • Ehemalige Namen:

    • F. Hoffmann-La Roche & Co. Aktiengesellschaft (bis 31.05.1989)

Tätigkeit

    • Firmenzweck:

    • Halten von Beteiligungen an Unternehmungen, die pharmazeutische und chemische Produkte aller Art fabrizieren und verkaufen. Die Beteiligung an sonstigen industriellen Unternehmungen und Holding-Gesellschaften ist gestattet.

    • Branche(n):

    • Firmensitzaktivitäten von anderen Gesellschaften

      Investmentgesellschaften

    • NOGA 2008:

    • 701002, 649901

Verbindungen

    • Tochtergesellschaften:

    • Basel, Buonas

      Im Ausland

    • Niederlassungen:

    • Im Ausland

News

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

24.01.2020

asel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.

“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “We remain committed to exploring the potential benefits of immunotherapy for more people with early cancers.”

The goal in treating MIUC early is to reduce the risk of the disease recurring or spreading to other parts of the body. More treatment options following surgery are needed as approximately half of people with MIUC will develop a recurrence of their disease within 2 years of surgery.1

In addition to ongoing Phase III studies in early and advanced bladder cancer, Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across several types of lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMvigor010 study
IMvigor010 is a global Phase III, open-label, randomised, controlled study designed to evaluate the efficacy and safety of adjuvant treatment with Tecentriq compared to observation in 809 people with MIUC, who are at high risk for recurrence following resection. The primary endpoint is DFS as assessed by investigator, which is defined as the time from randomisation to invasive urothelial cancer recurrence or death.

About bladder cancer and muscle-invasive urothelial cancer
In 2018, there were over half a million new cases of bladder cancer diagnosed globally, with approximately 200,000 deaths from the disease.2 Urothelial cancer is the most common type of bladder cancer, accounting for about 90–95% of all cases.3 MIUC is a type of urothelial cancer that has spread into the muscle of the bladder, ureter or renal pelvis.4 Approximately 25% of new cases of bladder cancer are diagnosed with muscle-invasive disease,5 which is associated with a poorer prognosis than non-MIUC.4

About Tecentriq
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is a cancer immunotherapy that has the potential to be used as a foundational combination partner with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. The development of Tecentriq and its clinical programme is based on our greater understanding of how the immune system interacts with tumours and how harnessing a person’s immune system combats cancer more effectively.

Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of non-small cell and small cell lung cancer, certain types of metastatic urothelial cancer, and in PD-L1-positive metastatic triple-negative breast cancer.

About Roche in cancer immunotherapy
For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.

By applying our seminal research in immune tumour profiling within the framework of the Roche-devised cancer immunity cycle, we are accelerating and expanding the transformative benefits with Tecentriq to a greater number of people living with cancer. Our cancer immunotherapy development programme takes a comprehensive approach in pursuing the goal of restoring cancer immunity to improve outcomes for patients.

To learn more about the Roche approach to cancer immunotherapy please follow this link: http://www.roche.com/research_and_development/what_we_are_working_on/oncology/cancer-immunotherapy.htm

Weitere News anzeigen

Nachbarschaft

Firmenprüfzeichen

Zeigen Sie Ihren Website-Besuchern, dass die Firma Roche Holding AG im Handelsregister eingetragen ist; bauen Sie dazu einfach diesen Code auf Ihrer Webseite ein.

Eintrag editieren

  • Eintrag editieren

  • Haben Sie Ergänzungen oder Korrekturen zum monetas-Eintrag der Roche Holding AG?

    Eintrag editieren
Anzeige
Anzeige